Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After drug eluting stent Implantation Receiving Clopidogrel.

Trial Profile

Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After drug eluting stent Implantation Receiving Clopidogrel.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin
  • Indications Coronary artery disease; Coronary stent thrombosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top